Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Purple Biotech Ltd. (PPBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Purple Biotech files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with registration statements on Forms F-1, F-3 and S-8, outline the company’s clinical-stage oncology strategy, financing activities, and corporate actions.
Through its Form 6-K reports, Purple Biotech furnishes press releases and corporate presentations that describe its oncology pipeline, including the CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219. Filings reference milestones such as manufacturing achievements for IM1240, preclinical and clinical data updates, European patent developments for NT219 combinations, and collaborations with academic institutions. They also include financial results, at-the-market offering agreements, and details of public offerings of American Depositary Shares and warrants.
Investors use Purple Biotech’s SEC filings to review quarterly and interim financial information furnished on Form 6-K, as well as capital markets transactions such as shelf registrations on Form F-3 and follow-on offerings. The filings also document corporate governance events, including notices and results of shareholder meetings, and incorporate certain reports by reference into existing registration statements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on pipeline progress, financing terms, and listing compliance matters. Users can follow new 6-K submissions in near real time as they are posted to EDGAR, and then drill into specific exhibits such as press releases or corporate presentations for more detail.
For those researching PPBT, this page serves as a central location to review Purple Biotech’s official SEC communications related to its clinical programs, financial position, and securities offerings, all organized chronologically with concise AI-generated overviews.
Purple Biotech Ltd. filed a report stating that it issued a press release titled “Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai.” The filing mainly serves to furnish this press release as an exhibit for U.S. investors. The update highlights new data related to Purple Biotech’s CAPTN-3 tri-specific antibody program, IM1240, developed in collaboration with the Icahn School of Medicine at Mount Sinai.
Purple Biotech Ltd. reported that it has expanded its CAPTN-3 portfolio by adding IM1305, described as a novel tri-specific antibody targeting TROP2. This update was communicated through a press release titled “Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2”, which is furnished as an exhibit to the report. The filing formally records this development for investors and provides official access to the accompanying press release.
Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.” The press release is included as Exhibit 99.1.
The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release—and all statements therein—into the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.
Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates “significant advantages” and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.